JP2014526488A - メラトニンの新規用途 - Google Patents
メラトニンの新規用途 Download PDFInfo
- Publication number
- JP2014526488A JP2014526488A JP2014530214A JP2014530214A JP2014526488A JP 2014526488 A JP2014526488 A JP 2014526488A JP 2014530214 A JP2014530214 A JP 2014530214A JP 2014530214 A JP2014530214 A JP 2014530214A JP 2014526488 A JP2014526488 A JP 2014526488A
- Authority
- JP
- Japan
- Prior art keywords
- melatonin
- sublingual
- administration
- use according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
- アルコール摂取後の、急性アルコール中毒、二日酔いの症状又は身体機能低下を治療するための、医薬として使用する、メラトニン又はその医薬的に許容される塩。
- 就寝前に1回、メラトニン0.1〜5mg、特に1.5〜3mg、が投与されることを特徴とする、請求項1に記載のメラトニン。
- 吸入エアゾル、舌下、経皮、経鼻、経口、直腸、静脈内投与からなる群から選択される形態を用いて、特に舌下ストリップ又は舌下液の舌下投与の形態を用いて、投与されることを特徴とする、請求項1又は2に記載のメラトニン。
- 遅延形態ではないことを特徴とする、請求項1乃至3のいずれか1項に記載のメラトニン。
- アルコール摂取後の、急性アルコール中毒、二日酔いの症状又は身体機能低下を患う哺乳類を治療する医薬の調製への、メラトニン又はその医薬的に許容される塩の使用。
- 就寝前の1回投与のために、メラトニンが調合されたことを特徴とする、請求項5に記載の使用。
- 投与される薬用量は、0.1〜5mg、特に1.5〜3mgであることを特徴とする、請求項5又は6に記載の使用。
- メラトニンは、吸入エアゾル、舌下、経皮、経鼻、経口、直腸、静脈内投与からなる群から選択される形態を用いて、特に舌下ストリップ又は舌下液の舌下投与の形態を用いて、投与されることを特徴とする、請求項5乃至7のいずれか1項に記載の使用。
- メラトニンは、遅延形態で投与されないことを特徴とする、請求項5乃至8のいずれか1項に記載の使用。
- アルコール飲料摂取後の、二日酔いの症状及び/又は身体機能損失を回避するための栄養補助食品としての、メラトニンの使用。
- 栄養補助食品は、就寝前に1度摂取されるために調製されたことを特徴とする、請求項10に記載の使用。
- 摂取される薬用量は、0.1〜5mg、特に1.5〜3mgであることを特徴とする、請求項10又は11に記載の使用。
- 栄養補助食品は、舌下ストリップ又は舌下液として投与され、摂取されることを特徴とする、請求項10乃至12のいずれか1項に記載の使用。
- メラトニン又はその医薬的に許容できる塩を含み、その含有量は、投与後に、エタノールの存在下で哺乳類の血中アセトアルデヒド組成物を増加させるのに有効な量である、医薬単位剤形。
- メラトニン又はその医薬的に許容できる塩を含み、その含有量は、投与後に、エタノールの存在下で哺乳類の身体機能の損失を減じるのに有効な量である、医薬単位剤形。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11181683.1 | 2011-09-16 | ||
EP20110181683 EP2570126B1 (en) | 2011-09-16 | 2011-09-16 | Use of melatonin for treating acute alcohol intoxication |
PCT/EP2012/067933 WO2013037883A1 (en) | 2011-09-16 | 2012-09-13 | New use of melatonine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014526488A true JP2014526488A (ja) | 2014-10-06 |
JP6184960B2 JP6184960B2 (ja) | 2017-08-23 |
Family
ID=46851981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530214A Active JP6184960B2 (ja) | 2011-09-16 | 2012-09-13 | メラトニンの新規用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10179122B2 (ja) |
EP (1) | EP2570126B1 (ja) |
JP (1) | JP6184960B2 (ja) |
CN (1) | CN103813791B (ja) |
AU (1) | AU2012307430B2 (ja) |
CA (1) | CA2848231C (ja) |
RU (1) | RU2633484C2 (ja) |
WO (1) | WO2013037883A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220016093A1 (en) * | 2018-12-07 | 2022-01-20 | Ajay Suman | Compositions for Aiding Liver Function |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149693A (ja) * | 1997-08-01 | 1999-02-23 | Forest Genetics Res Inst | ウルシ抽出物を含む抗癌剤組成物 |
JP2007510716A (ja) * | 2003-11-07 | 2007-04-26 | オーキー ナチュラル カンパニー,リミテッド | 木酢液より抽出したグアヤコール系成分及びシリンゴール系成分を含有する薬学的組成物 |
JP2007517040A (ja) * | 2003-12-24 | 2007-06-28 | セプレイコー インコーポレイテッド | 睡眠の質を改善するためのメラトニン併用療法 |
US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
WO2008148015A1 (en) * | 2007-05-24 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
JP2009539969A (ja) * | 2006-06-23 | 2009-11-19 | ザ プロクター アンド ギャンブル カンパニー | メラトニン成分及びフラバノール成分を含む組成物及びキット |
JP2010523673A (ja) * | 2007-04-11 | 2010-07-15 | マッカーティ,ジョン,エイ. | メラトニンタブレットならびに調剤及び使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2718020B1 (fr) | 1994-04-01 | 1996-05-31 | Biotec Centre Sa | Composition galénique mucoadhésive hétérofonctionnelle. |
EP0867181A1 (en) | 1997-03-26 | 1998-09-30 | Franciscus Wilhelmus Henricus Maria Merkus | Nasal melatonin composition |
US20020048551A1 (en) * | 1999-04-06 | 2002-04-25 | Keller Brian C. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
IL149377A (en) | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
UA55668A (uk) | 2002-04-12 | 2003-04-15 | Інститут Геронтології Академії Медичних Наук України | Спосіб лікування та попередження порушень діяльності серцево-судинної системи стресового походження у людей літнього віку |
RU2250778C1 (ru) | 2004-02-26 | 2005-04-27 | Мясников Дмитрий Николаевич | Средство, снижающее неблагоприятные последствия острой алкогольной интоксикации |
US9028881B2 (en) | 2005-05-02 | 2015-05-12 | Cj Cheiljedang Corporation | Composition for preventing and treating hangover |
GB2434099A (en) * | 2006-01-12 | 2007-07-18 | Roger Coghill | Very low dosage melatonin compositions and their use in the treatment of the adverse effects of exposure to electromagnetic fields and radiation |
US8691297B2 (en) * | 2010-09-01 | 2014-04-08 | Nippon Suisan Kaisha, Ltd. | Alcoholic injury mitigating agent |
-
2011
- 2011-09-16 EP EP20110181683 patent/EP2570126B1/en active Active
-
2012
- 2012-09-13 CN CN201280043949.9A patent/CN103813791B/zh active Active
- 2012-09-13 JP JP2014530214A patent/JP6184960B2/ja active Active
- 2012-09-13 AU AU2012307430A patent/AU2012307430B2/en active Active
- 2012-09-13 US US14/344,999 patent/US10179122B2/en active Active
- 2012-09-13 RU RU2014115196A patent/RU2633484C2/ru active
- 2012-09-13 WO PCT/EP2012/067933 patent/WO2013037883A1/en active Application Filing
- 2012-09-13 CA CA2848231A patent/CA2848231C/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149693A (ja) * | 1997-08-01 | 1999-02-23 | Forest Genetics Res Inst | ウルシ抽出物を含む抗癌剤組成物 |
JP2007510716A (ja) * | 2003-11-07 | 2007-04-26 | オーキー ナチュラル カンパニー,リミテッド | 木酢液より抽出したグアヤコール系成分及びシリンゴール系成分を含有する薬学的組成物 |
JP2007517040A (ja) * | 2003-12-24 | 2007-06-28 | セプレイコー インコーポレイテッド | 睡眠の質を改善するためのメラトニン併用療法 |
JP2009539969A (ja) * | 2006-06-23 | 2009-11-19 | ザ プロクター アンド ギャンブル カンパニー | メラトニン成分及びフラバノール成分を含む組成物及びキット |
US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
JP2010523673A (ja) * | 2007-04-11 | 2010-07-15 | マッカーティ,ジョン,エイ. | メラトニンタブレットならびに調剤及び使用方法 |
WO2008148015A1 (en) * | 2007-05-24 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
Non-Patent Citations (1)
Title |
---|
ALCOHOL & ALCOHOLISM, vol. 34, no. 6, JPN6016018028, 1999, pages 842 - 850, ISSN: 0003318682 * |
Also Published As
Publication number | Publication date |
---|---|
US20150111941A1 (en) | 2015-04-23 |
CA2848231A1 (en) | 2013-03-21 |
RU2633484C2 (ru) | 2017-10-12 |
CN103813791B (zh) | 2016-06-15 |
AU2012307430A1 (en) | 2014-04-17 |
AU2012307430B2 (en) | 2017-08-31 |
EP2570126B1 (en) | 2014-03-26 |
WO2013037883A1 (en) | 2013-03-21 |
CA2848231C (en) | 2019-12-31 |
RU2014115196A (ru) | 2015-10-27 |
CN103813791A (zh) | 2014-05-21 |
EP2570126A1 (en) | 2013-03-20 |
US10179122B2 (en) | 2019-01-15 |
JP6184960B2 (ja) | 2017-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5513126B2 (ja) | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 | |
JP2014528474A5 (ja) | ||
JP6353577B2 (ja) | 組み合わせ組成物 | |
TW200534852A (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
JP2018507243A5 (ja) | ||
KR102597910B1 (ko) | 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 | |
Gautam et al. | Evaluation of the efficacy of methylprednisolone, etoricoxib and a combination of the two substances to attenuate postoperative pain and PONV in patients undergoing laparoscopic cholecystectomy: a prospective, randomized, placebo-controlled trial | |
JP2024026871A (ja) | 慢性便秘症を治療するための医薬組成物 | |
JP6184960B2 (ja) | メラトニンの新規用途 | |
JP2019504040A (ja) | 中等度〜重度のインフルエンザの処置 | |
WO2004080414A2 (en) | Composition and method for treating inflammations by reducing c-reactive protein | |
WO2009094811A1 (fr) | Préparation d'un mélange acide de gelée royale et son application | |
TW200831072A (en) | Non-steroidal anti-inflammatory drugs for cough | |
CN101085073A (zh) | 桑叶杏仁口服液 | |
CN109646438A (zh) | 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用 | |
US11464756B1 (en) | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof | |
EP4181887A1 (en) | Pde3 inhibitors for treating viral infections | |
RU2404976C1 (ru) | Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения | |
RU2345763C1 (ru) | Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин | |
RU2131733C1 (ru) | Способ ослабления и профилактики абстинентного синдрома и средство для его осуществления | |
WO2022126255A1 (en) | Antioxidant nutritional supplement for immune system support | |
JP2022071083A (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
CN107648226A (zh) | 一种治疗偏头痛的药物组合物及其制备方法 | |
CN106728023A (zh) | 一种治疗胆结石的中医药物配方 | |
Vital | Flavogard (Pycnogenol) may protect from five major cardiovascular risk factors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170726 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6184960 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |